Valor predictivo de las troponinas para mortalidad intrahospitalaria en adultos con COVID-19 en la Clínica General del Norte durante enero a junio de 2021

dc.contributorCano Rivera, Rodolfo
dc.contributorVarela Prieto, Lourdes
dc.creatorMurgas Cañas, Carlos Hernando
dc.creatorOspino Guerra, María Clara
dc.date.accessioned2024-02-07T19:42:41Z
dc.date.accessioned2024-05-16T21:41:41Z
dc.date.available2024-02-07T19:42:41Z
dc.date.available2024-05-16T21:41:41Z
dc.date.created2024-02-07T19:42:41Z
dc.identifierhttps://hdl.handle.net/10901/28377
dc.identifier.urihttps://repositorioslatinoamericanos.uchile.cl/handle/2250/9488407
dc.description.abstractObjetivo: Determinar el valor predictivo de las troponinas cardíacas para mortalidad intrahospitalaria en adultos hospitalizados con COVID-19 durante enero a junio de 2021. Materiales y métodos: Estudio de casos y controles anidado en una cohorte retrospectiva, que incluyó sujetos de 18 años en adelante con diagnóstico confirmado de COVID-19 hospitalizados entre enero y junio de 2021; se describieron las variables demográficas y paraclínicas de los pacientes y su relación con la condición al egreso; se estimaron las características operativas (sensibilidad, especificidad y valores predictivos) de las troponinas elevadas frente a la mortalidad. Resultados: Se incluyeron 358 participantes, de los cuales 47,8% eran mujeres, la edad promedio fue de 65,1+/-14,9 años. Las comorbilidades más frecuentes fueron hipertensión arterial (53,1%), obesidad (31,6%) y diabetes mellitus (21,5%). Todas las variables estudiadas (excepto el sexo) presentaron diferencias estadísticamente significativas (p<0,05) respecto a mortalidad, siendo la elevación de troponinas el principal factor, con un OR de 9,4 (IC95%: 5,5-16,0). Los pacientes con elevación de troponinas presentaron una mortalidad intrahospitalaria mayor (55,6%) frente al grupo sin elevación (11,7%). La sensibilidad y especificidad de este biomarcador fue de 77,9% y 72,7% respectivamente. El valor predictivo positivo de la elevación de troponinas fue de 55,6% y su valor predictivo negativo fue de 88,3% para mortalidad intrahospitalaria. Conclusión: La elevación de troponinas en los sujetos con COVID-19 tiene una correlación positiva con la mortalidad intrahospitalaria de forma independiente a otras condiciones como grupo etario, comorbilidades o requerimiento de oxigenoterapia. Por otro lado, las troponinas normales tienen un buen valor predictivo negativo que permite predecir mayor probabilidad de supervivencia al egreso.
dc.relationWoodall MNJ, Masonou T, Case KM, Smith CM. Human models for COVID- 19 research. J Physiol. 2021;599(18):4255–67
dc.relationGautret P, Million M, Jarrot PA, Camoin-Jau L, Colson P, Fenollar F, et al. Natural history of COVID-19 and therapeutic options. Expert Rev Clin Immunol. 2020;16(12):1159–84
dc.relationZheng Z, Peng F, Xu B, Zhao J, Liu H, Peng J. Risk factors of critical & mortal COVID-19 cases: A systematic literature review and meta-analysis. J Infect. 2020;81(2):e16–25
dc.relationTian W, Jiang W, Yao J, Nicholson CJ, Li RH, Sigurslid HH, et al. Predictors of mortality in hospitalized COVID-19 patients: A systematic review and meta- analysis. J Med Virol. 2020;92(10):1875–83
dc.relationZinellu A, Sotgia S, Fois AG, Mangoni AA. Serum CK-MB, COVID-19 severity and mortality: An updated systematic review and meta-analysis with meta- regression. Adv Med Sci. 2020;66(2):304–14
dc.relationBeltrán FM. La Sociedad Colombiana de Cardiología y Cirugía Cardiovascular y la pandemia COVID-19. Rev Colomb Cardiol. 2020;27(2):69–72
dc.relationSaavedra CA. Consenso colombiano de atención, diagnóstico y manejo de la infección por SARS-COV-2/COVID-19 en establecimientos de atención de la salud. Infectio. 2020;24(3):1–2
dc.relationGao L, Jiang D, Wen XS, Cheng XC, Sun M, He B, et al. Prognostic value of NT-proBNP in patients with severe COVID-19. Respir Res. 2020;21(1):1–7
dc.relationMcKinney J, Connelly KA, Dorian P, Fournier A, Goodman JM, Grubic N, et al. COVID-19–Myocarditis and Return to Play: Reflections and Recommendations From a Canadian Working Group. Can J Cardiol. 2021;37(8):1165–74
dc.relationCañón-Montañez W, Santos ÁBS, Foppa M. Strain longitudinal global: un parámetro útil para evaluar disfunción ventricular izquierda subclínica en el síndrome metabólico. Rev Colomb Cardiol. 2016;23(2):112–9
dc.relationSun W, Zhang Y, Wu C, Xie Y, Peng L, Nie X, et al. Incremental prognostic value of biventricular longitudinal strain and high-sensitivity troponin I in COVID-19 patients. Echocardiography. 2021;38(8):1272–81
dc.relationParis S, Inciardi RM, Lombardi CM, Tomasoni D, Ameri P, Carubelli V, et al. 60 Implications of atrial fibrillation on the clinical course and outcomes of hospitalized COVID-19 patients: Results of the Cardio-COVID-Italy multicentre study. Europace. 2021;23(10):1603–11
dc.relationHendren NS, Drazner MH, Bozkurt B. Description and Proposed Management of the Acute COVID-19 Cardiovascular Syndrome Middle Eastern respiratory syndrome. Circulation. 2020;9(141):1903–1914
dc.relationSattar Y, Ullah W, Rauf H, Virk H ul H, Yadav S, Chowdhury M, et al. COVID- 19 cardiovascular epidemiology, cellular pathogenesis, clinical manifestations and management. IJC Hear Vasc [Internet]. 2020;29(2020):100589. Available from: https://doi.org/10.1016/j.ijcha.2020.100589
dc.relationCannata F, Bombace S, Stefanini GG. Marcadores cardiacos en pacientes con COVID-19: un instrumento práctico en tiempos difíciles. Rev Española Cardiol. 2021;10–2
dc.relationStefanini GG, Chiarito M, Ferrante G, Cannata F, Azzolini E, Viggiani G, et al. Early detection of elevated cardiac biomarkers to optimise risk stratification in patients with COVID-19. Heart. 2020;106(19):1512–8
dc.relationQin JJ, Cheng X, Zhou F, Lei F, Akolkar G, Cai J, et al. Redefining cardiac biomarkers in predicting mortality of inpatients with COVID-19. Hypertension. 2020;1104–12
dc.relationZhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054–62
dc.relationDeng P, Ke Z, Ying B, Qiao B, Yuan L. The diagnostic and prognostic role of myocardial injury biomarkers in hospitalized patients with COVID-19. Clin Chim Acta [Internet]. 2020; 510:186–90. Available from: https://doi.org/10.1016/j.cca.2020.07.018
dc.relationJunior GLG de A, Braga F, Jorge JK, Nobre GF, Kalichsztein M, de Faria P de MP, et al. Prognostic value of troponin-t and b-type natriuretic peptide in patients hospitalized for covid-19. Arq Bras Cardiol. 2020;115(4):660–6
dc.relationOmland T, Prebensen C, Røysland R, Søvik S, Sørensen V, Røsjø H, et al. Established Cardiovascular Biomarkers Provide Limited Prognostic Information in Unselected Patients Hospitalized With COVID-19. Circulation. 2020;142(19):1878–80
dc.relationMetkus TS, Sokoll LJ, Barth AS, Czarny MJ, Hays AG, Lowenstein CJ, et al. Myocardial Injury in Severe COVID-19 Compared with Non-COVID-19 Acute 61 Respiratory Distress Syndrome. Circulation. 2021;553–65
dc.relationGuo T, Fan Y, Chen M, Wu X, Zhang L, He T, et al. Cardiovascular Implications of Fatal Outcomes of Patients with Coronavirus Disease 2019 (COVID-19). JAMA Cardiol. 2020;5(7):811–8
dc.relationYu CM, Wong RSM, Wu EB, Kong SL, Wong J, Yip GWK, et al. Cardiovascular complications of severe acute respiratory syndrome. Postgrad Med J. 2006;82(964):140–4
dc.relationMadjid M, Safavi-Naeini P, Solomon SD, Vardeny O. Potential Effects of Coronaviruses on the Cardiovascular System: A Review. JAMA Cardiol. 2020;5(7):831–40
dc.relationClerkin K, Fried J, Raikhelkar J, Sayer G, Griffin J, Masoumi A, et al. COVID- 19 and cardiovascular disease. Circulation. 2020;141(20):1648–55
dc.relationHuang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497–506
dc.relationYang F, Wang J, Li W, Xu Y, Wan K, Zeng R, et al. The prognostic value of late gadolinium enhancement in myocarditis and clinically suspected myocarditis: systematic review and meta-analysis. Eur Radiol. 2020;30(5):2616–26
dc.relationVélez M, Velásquez P, Acosta J, Vera C, Santiago J, Jimenez C, et al. Factores clínicos pronósticos de enfermedad grave y mortalidad en pacientes con COVID-19. Univ Antioquia [Internet]. 2020;1(1):57. Available from: http://fi-admin.bvsalud.org/document/view/rpncv NS
dc.relationManocha KK, Kirzner J, Ying X, Yeo I, Peltzer B, Ang B, et al. Troponin and other biomarker levels and outcomes among patients hospitalized with COVID-19: Derivation and validation of the Ha2T2 COVID-19 mortality risk score. J Am Heart Assoc. 2021;10(6
dc.relationShi S, Qin M, Shen B, Cai Y, Liu T, Yang F, et al. Association of Cardiac Injury with Mortality in Hospitalized Patients with COVID-19 in Wuhan, China. JAMA Cardiol. 2020;5(7):802–10
dc.relationSmilowitz NR, Kunichoff D, Garshick M, Shah B, Pillinger M, Hochman JS, et al. C-reactive protein and clinical outcomes in patients with COVID-19. Eur Heart J. 2021 Jun;42(23):2270–9
dc.relationYitbarek GY, Walle Ayehu G, Asnakew S, Ayele FY, Bariso Gare M, Mulu AT, et al. The role of C-reactive protein in predicting the severity of COVID-19 62 disease: A systematic review. SAGE open Med. 2021; 9:20503121211050756
dc.relationSoni M, Gopalakrishnan R, Vaishya R, Prabu P. D-dimer level is a useful predictor for mortality in patients with COVID-19: Analysis of 483 cases. Diabetes Metab Syndr. 2020;14(6):2245–9
dc.relationYao Y, Cao J, Wang Q, Shi Q, Liu K, Luo Z, et al. D-dimer as a biomarker for disease severity and mortality in COVID-19 patients: a case control study. J intensive care. 2020; 8:49
dc.relationBartziokas K, Kostikas K. Lactate dehydrogenase, COVID-19 and mortality. Vol. 156, Medicina clinica. Spain; 2021. p. 37
dc.relationDeng F, Zhang L, Lyu L, Lu Z, Gao D, Ma X, et al. Increased levels of ferritin on admission predicts intensive care unit mortality in patients with COVID-19. Med Clin (Barc). 2021 Apr;156(7):324–31
dc.relationMesas AE, Cavero-Redondo I, Álvarez-Bueno C, Cabrera MAS, de Andrade SM, Sequí-Dominguez I, et al. Predictors of in-hospital COVID-19 mortality: A comprehensive systematic review and meta-analysis exploring differences by age, sex and health conditions. PLoS One. 2020;15(11 November):1–23
dc.relationMoutchia J, Pokharel P, Kerri A, McGaw K, Uchai S, Nji M, et al. Clinical laboratory parameters associated with severe or critical novel coronavirus disease 2019 (COVID-19): A systematic review and meta-analysis. PLoS One [Internet]. 2020;15(10 October):1–25. Available from: http://dx.doi.org/10.1371/journal.pone.0239802
dc.relationGhahramani S, Tabrizi R, Lankarani KB, Kashani SMA, Rezaei S, Zeidi N, et al. Laboratory features of severe vs. non-severe COVID-19 patients in Asian populations: A systematic review and meta-analysis. Eur J Med Res [Internet]. 2020;25(1):1–10. Available from: https://doi.org/10.1186/s40001-020-00432-3
dc.relationAli AM, Rostam HM, Fatah MH, Noori CM, Ali KM, Tawfeeq HM. Serum troponin, D-dimer, and CRP level in severe coronavirus (COVID-19) patients. Immunity, Inflamm Dis. 2022;10(3):1–10
dc.relationVelavan TP, Meyer CG. Mild versus severe COVID-19: Laboratory markers. Int J Infect Dis. 2020;95(January):304–7
dc.relationMcKinney J, Connelly KA, Dorian P, Fournier A, Goodman JM, Grubic N, et al. COVID-19–Myocarditis and Return to Play: Reflections and Recommendations From a Canadian Working Group. Can J Cardiol [Internet]. 2020; Available from: https://doi.org/10.1016/j.cjca.2020.11.007
dc.relationPapageorgiou N, Sohrabi C, Prieto Merino D, Tyrlis A, Atieh AE, Saberwal B, et al. High sensitivity troponin and COVID-19 outcomes. Acta Cardiol [Internet]. 2022;77(1):81–8. Available from: https://doi.org/10.1080/00015385.2021.1887586
dc.relationZhu F, Li W, Lin Q, Xu M, Du J, Li H. Myoglobin and troponin as prognostic factors in patients with COVID-19 pneumonia. Med Clin (Barc). 2021;157(January):164–71
dc.relationAl B, Torres P, Ramos-tuarez F, Dewaswala N, Abdallah A. Cardiac Troponin- I and COVID-19: A Prognostic Tool for In-Hospital Mortality. 2020;11(6):398– 404
dc.relationWang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical Characteristics of 138 Hospitalized Patients with 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA - J Am Med Assoc. 2020;323(11):1061–9
dc.relationPonti G, Maccaferri M, Ruini C, Tomasi A, Ozben T. Biomarkers associated with COVID-19 disease progression. Crit Rev Clin Lab Sci [Internet]. 2020;0(0):389–99. Available from: https://doi.org/10.1080/10408363.2020.1770685
dc.relationImazio M, Klingel K, Kindermann I, Brucato A, De Rosa FG, Adler Y, et al. COVID-19 pandemic and troponin: indirect myocardial injury, myocardial inflammation or myocarditis? Heart. 2020 Aug;106(15):1127–31
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectCOVID-19
dc.subjectMortalidad
dc.subjectTroponinas
dc.subjectValor predictivo
dc.subjectInjuria miocárdica
dc.titleValor predictivo de las troponinas para mortalidad intrahospitalaria en adultos con COVID-19 en la Clínica General del Norte durante enero a junio de 2021


Este ítem pertenece a la siguiente institución